Nutlin-3a

Catalog No.S8059

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nutlin-3a Chemical Structure

Nutlin-3a Chemical Structure
Molecular Weight: 581.49

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare Mdm2 Inhibitors
    Compare Mdm2 Products
  • Research Area

Product Description

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Targets p53/MDM2 interaction [3]
(Cell-free assay)
IC50 90 nM
In vitro Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11NE\FVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPaPWhKSzVyPUCuOlEzOzdizszNNF76TGRUSU6JRWK=
H4NWDaVYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLXWJpKSzVyPUCuOlYzQCEQvF2=NF2xVFlUSU6JRWK=
PA-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPnWmZnUUN3ME2wMlg4ODl4IN88US=>M4nZenNCVkeHUh?=
NKM-1NVPzSWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7mTWM2OD1zLkC0PVMyKM7:TR?=Mmi0V2FPT0WU
NEC8MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFwMkG1O|Ih|ryPNFG2T3VUSU6JRWK=
EoL-1-cellMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPOb5pKSzVyPUGuNlY4ODFizszNMWDTRW5ITVJ?
K5M1PNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrFWpBKSzVyPUGuOFIxPzJizszNMn;HV2FPT0WU
QIMR-WILMmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\sXGlEPTB;MT62NFg2PCEQvF2=MmTLV2FPT0WU
MOLT-16NGruPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jqbWlEPTB;MT63PFYxPCEQvF2=M1PuPXNCVkeHUh?=
CHP-212NFTKTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLiTWM2OD1zLkixN|Y6KM7:TR?=NXXLe4x1W0GQR1XS
CTB-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorNTWM2OD1{LkCyNlQ3KM7:TR?=MmnSV2FPT0WU
MOLT-4Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7LPXhKSzVyPUKuN|I5PTNizszNNWLQenN6W0GQR1XS
A101DNYTyR|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXicZpHUUN3ME2yMlM2ODFizszNMWXTRW5ITVJ?
DOHH-2Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJwNEKyO|kh|ryPNGm3RnRUSU6JRWK=
ES4NXvnco1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\2TWM2OD1{LkSzNVU2KM7:TR?=MYrTRW5ITVJ?
SW780MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnSTWM2OD1{LkWwPFg{KM7:TR?=M3XLfXNCVkeHUh?=
VA-ES-BJMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1y2d2lEPTB;Mj61OFEyKM7:TR?=NXHROXpOW0GQR1XS
RPMI-8866NGXH[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j2VGlEPTB;Mj61OlIyPCEQvF2=NYnhOGxZW0GQR1XS
ML-2MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Xz[mlEPTB;Mj61OlU4PiEQvF2=NUn4fGpmW0GQR1XS
MSTO-211HMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrNTWM2OD1{LkW3OFUyKM7:TR?=MWrTRW5ITVJ?
JVM-3MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvmO4lKSzVyPUKuOVk{OjRizszNM3yxe3NCVkeHUh?=
A3-KAWMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3H0VmlEPTB;Mj62NVgyQCEQvF2=M1zXe3NCVkeHUh?=
DK-MGNF7sPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHDTWM2OD1{Lk[yOFcyKM7:TR?=MUjTRW5ITVJ?
LNCaP-Clone-FGCNYXHNlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHn5boxKSzVyPUKuOlQ{OThizszNNIDKT|RUSU6JRWK=
HT-144MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3TN3ZKSzVyPUKuOlQ2PzdizszNMle0V2FPT0WU
NB69MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{ThVWlEPTB;Mj62OVM{PCEQvF2=MV3TRW5ITVJ?
A172MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInifopKSzVyPUKuOlc2QDhizszNMn7sV2FPT0WU
RS4-11MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfQdG9KSzVyPUKuO|I1ODdizszNNU\MSo5pW0GQR1XS
DU-4475M2HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjzdoZKSzVyPUKuO|k2ODJizszNMnL6V2FPT0WU
SJSA-1NXnF[3JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT2TWM2OD1{LkiyOVU3KM7:TR?=NUjYO4dGW0GQR1XS
BV-173MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PRT2lEPTB;Mj64OFQ{QSEQvF2=M3fqZXNCVkeHUh?=
U-2-OSMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PGemlEPTB;Mj65NVA4KM7:TR?=Mn;YV2FPT0WU
CHP-134MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\3TWM2OD1{LkmzPFgzKM7:TR?=NV\QUI11W0GQR1XS
D-502MGMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvsVW43UUN3ME2yMlk4OTV2IN88US=>MnHyV2FPT0WU
KS-1NWjzXldFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml20TWM2OD1|LkCxOlI{KM7:TR?=Ml\vV2FPT0WU
A204M4Tre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUL0c|RLUUN3ME2zMlA2PTh6IN88US=>NVfWT|BsW0GQR1XS
KGNMnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD2TWM2OD1|LkC4OFk3KM7:TR?=MVHTRW5ITVJ?
NCI-H292NWLLcFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\NdGlEPTB;Mz6xNlAzQCEQvF2=MknUV2FPT0WU
CAKI-1NWr3TnVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\TTWM2OD1|LkGyOlk1KM7:TR?=MXvTRW5ITVJ?
C2BBe1NWm0dY1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGSzXoZKSzVyPUOuNVcxOjZizszNMWPTRW5ITVJ?
NB10NYe5Sm96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzRUWdMUUN3ME2zMlIxQTZ4IN88US=>MVHTRW5ITVJ?
MHH-NB-11MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmKyTWM2OD1|LkK2PFI4KM7:TR?=M{\kSXNCVkeHUh?=
NCI-SNU-1MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYSyXINsUUN3ME2zMlI4QDR|IN88US=>NF\U[JJUSU6JRWK=
HCT-116NXzW[Go4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfiTJBKSzVyPUOuN|A{OzVizszNM2j3VHNCVkeHUh?=
G-401MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTNwM{[zNlIh|ryPNVK1TXJlW0GQR1XS
MN-60M{TSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXr3R5lvUUN3ME2zMlQ1ODl{IN88US=>NHnBclJUSU6JRWK=
SW982MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXzWIJKSzVyPUOuOVA5PDhizszNNWXxboRkW0GQR1XS
RKONG\YNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTNwNUO5N|Yh|ryPNEP3PJpUSU6JRWK=
D-283MEDMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTNwNUe5PFYh|ryPNVrTcJF6W0GQR1XS
LB996-RCCM1Xoc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTNwNkK1OVgh|ryPM4P1UXNCVkeHUh?=
A549NWfFUmd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nOT2lEPTB;Mz62N|U2OiEQvF2=M17vVXNCVkeHUh?=
LB2241-RCCNGrqTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjEVpNKSzVyPUOuOlU4ODhizszNMki3V2FPT0WU
SK-HEP-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHITGxCUUN3ME2zMlc1Ojl5IN88US=>MU\TRW5ITVJ?
G-402NH;RXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTNwOEC4N|Ih|ryPNX3HN4lrW0GQR1XS
GOTONFjJNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTNwOESzN|Mh|ryPM2Hr[XNCVkeHUh?=
LOXIMVINGrO[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDscZdwUUN3ME2zMlg2Pjd3IN88US=>M{f1c3NCVkeHUh?=
NH-12MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mme3TWM2OD12LkCxPVU6KM7:TR?=NIfNZ5RUSU6JRWK=
CTV-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fE[GlEPTB;ND6wO|k4OyEQvF2=MXjTRW5ITVJ?
CP50-MEL-BNVPISpU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTRwMkSzPVIh|ryPNWLGbotWW0GQR1XS
RH-18MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvPcFNKSzVyPUSuNlc4ODZizszNMnXmV2FPT0WU
NB17NX\5cFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHyTWM2OD12LkOxO|Y5KM7:TR?=MnjxV2FPT0WU
A375NWLwXpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrSUYxqUUN3ME20MlM{PTJ2IN88US=>M4DNW3NCVkeHUh?=
IST-MES1NWrkc|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnNbWNoUUN3ME20MlQyPDFzIN88US=>MlnqV2FPT0WU
MZ2-MELMl[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jqWWlEPTB;ND61NFE2PSEQvF2=NFrEVolUSU6JRWK=
CAL-54MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInrcXZKSzVyPUSuOVMxOTlizszNMlnSV2FPT0WU
NCI-H28MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7GTWM2OD12Lk[yO|E4KM7:TR?=NV6wWXdmW0GQR1XS
D-247MGMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVv0fWR1UUN3ME20Mlc2ODd{IN88US=>MV3TRW5ITVJ?
NCI-H460MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHXTWM2OD12LkmxNVI4KM7:TR?=MlLlV2FPT0WU
MCF7M1fpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1q5WWlEPTB;NT60OFI1PCEQvF2=M1;WcXNCVkeHUh?=
697NUXkd4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHzUGU{UUN3ME21MlQ1PTVizszNNYnGZWgxW0GQR1XS
ONS-76NVvMVIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGq2foFKSzVyPUWuOVcxODlizszNNHvQZ3BUSU6JRWK=
C32MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXTTWM2OD13Lk[wNFI6KM7:TR?=MnXoV2FPT0WU
OS-RC-2NWHsT2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nnbmlEPTB;NT63N|g5PyEQvF2=M4S4OnNCVkeHUh?=
MEL-HONXP2enpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTVwOEW2Olch|ryPMXfTRW5ITVJ?
LoVoMkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTZwMEG2NlQh|ryPMVvTRW5ITVJ?
AGSMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrLcHVrUUN3ME22MlE1QDJ6IN88US=>M1q4fHNCVkeHUh?=
GI-ME-NM2nSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i3NWlEPTB;Nj6yNlQzOSEQvF2=MUTTRW5ITVJ?
H-EMC-SSNUfNZ4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnrW|hyUUN3ME22MlM5PiEQvF2=NUCyb3c2W0GQR1XS
RVH-421MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1SyeWlEPTB;Nj60NlQzQCEQvF2=NGjnfnpUSU6JRWK=
SW954NWfv[XhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfSUlV7UUN3ME22MlU2PTd{IN88US=>MXHTRW5ITVJ?
NB5NVTJOoloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTZwNU[xPFMh|ryPM3Pk[nNCVkeHUh?=
NCI-H2122MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LwN2lEPTB;Nj61PFc6OyEQvF2=NHHZcXhUSU6JRWK=
AM-38M4XrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTZwN{W2N|kh|ryPNFPweFVUSU6JRWK=
KNS-81-FDNHzOW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\GdIJKSzVyPU[uO|Y1QTRizszNMWjTRW5ITVJ?
LS-513M1rERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvSTWM2OD14Lke5NFI3KM7:TR?=MV;TRW5ITVJ?
A427MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qwN2lEPTB;Nj64O|gzQSEQvF2=MWrTRW5ITVJ?
WM-115NYPQd5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTZwOUOyN{DPxE1?NEjWZmNUSU6JRWK=
COLO-829NEfrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf4TJVKSzVyPUeuNlQyQDhizszNMlznV2FPT0WU
NCI-H1650NIm1[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTdwM{myNlgh|ryPMnXLV2FPT0WU
NCI-H358MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTdwNES4O|kh|ryPMnXzV2FPT0WU
HT-1080NGDy[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;NRVFRUUN3ME23MlQ5OjV2IN88US=>MVjTRW5ITVJ?
HCC2218NVvtUIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTdwNkK5O{DPxE1?NHr6SVhUSU6JRWK=
NCI-H661MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTdwOEewOlkh|ryPNF;0R4dUSU6JRWK=
KM-H2MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfpfYhsUUN3ME23Mlg5Pjl2IN88US=>NUTuUIZ2W0GQR1XS
RPMI-2650MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTdwOUS0NVQh|ryPMkftV2FPT0WU
NCI-H226MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jTPGlEPTB;OD6yNVEzOiEQvF2=Mo\LV2FPT0WU
MKN45M1[2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTZe3pKSzVyPUiuNlY3ODJizszNMnP1V2FPT0WU
D-392MGMl;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37SeWlEPTB;OD61NlczOiEQvF2=NV3TRYZqW0GQR1XS
RCC10RGBM2fRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr6TWM2OD16Lki2Olk2KM7:TR?=NYTGTIhmW0GQR1XS
CAL-51MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XtVmlEPTB;OT6xNFI2OSEQvF2=NUL3cm9uW0GQR1XS
COLO-678M{TNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzRZmdIUUN3ME25MlMzQDFzIN88US=>M4jDVHNCVkeHUh?=
SK-MEL-24MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvleWlwUUN3ME25MlU2QDV4IN88US=>MmXWV2FPT0WU
SK-MEL-30M{\MPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;JdId1UUN3ME25Mlk1PDd4IN88US=>MXvTRW5ITVJ?
MMAC-SFMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\NbWlEPTB;MUCuN|k3OSEQvF2=MmXXV2FPT0WU
NTERA-S-cl-D1NF;4V5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvHZWJKSzVyPUGwMlY2ODhizszNM1zhdHNCVkeHUh?=
NB12MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXwTWM2OD1zMT61NFMh|ryPMVjTRW5ITVJ?
UACC-257MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGe4cpRKSzVyPUGxMlg3QTVizszNNX;zR3JlW0GQR1XS
LAN-6NYnYTYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF[2XIdKSzVyPUGxMlk6OjhizszNNXvkc295W0GQR1XS
SW1573MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF{LkOwPFYh|ryPM2T6TnNCVkeHUh?=
NMC-G1NHjWdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rHUGlEPTB;MUKuOFE4PSEQvF2=NXTaRoZrW0GQR1XS
SHP-77NYXkUHB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3lTodUUUN3ME2xNk42PTd2IN88US=>NF7UNHJUSU6JRWK=
IGROV-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHFNGpKSzVyPUGyMlY2PzNizszNMkLLV2FPT0WU
22RV1M2X6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTUSodKSzVyPUGyMlgxPTlizszNMmXJV2FPT0WU
SK-MEL-3NELFTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfvTWM2OD1zMz6zPVc{KM7:TR?=NEHwXI1USU6JRWK=
NCI-H1563MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTF|LkSyNFIh|ryPM{S3b3NCVkeHUh?=
IGR-1M4fwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWry[5NkUUN3ME2xOE4xOzR5IN88US=>MnzKV2FPT0WU
EW-3NVXnbYczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmx[2p[UUN3ME2xOE4yPjN7IN88US=>NHTYRphUSU6JRWK=
JEG-3NIftOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLBe41KSzVyPUG0MlQ6PTNizszNNUXZUJdvW0GQR1XS
ES3MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zMSWlEPTB;MUSuOlU3OiEQvF2=NInPdmxUSU6JRWK=
MDA-MB-175-VIINUnne2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfVemg6UUN3ME2xOE44OTFzIN88US=>NWnxO2QzW0GQR1XS
P30-OHKMmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;iTVlKSzVyPUG1MlA1QTZizszNM1f5eHNCVkeHUh?=
GP5dNITaW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHT2ZlhKSzVyPUG1MlE1PjZizszNNXXKRpNSW0GQR1XS
HMV-IIMkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLUTWM2OD1zNT6zN|M{KM7:TR?=MlfuV2FPT0WU
COLO-679M4DZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTF3LkWwNUDPxE1?M3zxeHNCVkeHUh?=
JARNULWNWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;BfplKSzVyPUG1MlczODVizszNMVfTRW5ITVJ?
NCI-H1666M3;DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSyU4lwUUN3ME2xOU46Ozl7IN88US=>MVHTRW5ITVJ?
SW48MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFe3bWJKSzVyPUG1Mlk2OTZizszNNX[xVVdRW0GQR1XS
NCI-H720MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e2bmlEPTB;MUWuPVk5QSEQvF2=NI[5WIdUSU6JRWK=
HT-1197NF3vZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTF4LkCzOVIh|ryPMlzBV2FPT0WU
HL-60M4D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlO0TWM2OD1zNj6wN|g1KM7:TR?=NWHNcVJQW0GQR1XS
BENMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfhSYJKSzVyPUG2MlU3OzhizszNMXnTRW5ITVJ?
HAL-01Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX74bHYzUUN3ME2xOk45QTB7IN88US=>MnLiV2FPT0WU
SW900M3\KSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;qTWM2OD1zNj65NVMzKM7:TR?=NFHVNZlUSU6JRWK=
SBC-1M4rLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzLRpZmUUN3ME2xO{42PDJ7IN88US=>M3jOUnNCVkeHUh?=
SH-4NEnxeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF5LkW4OFEh|ryPNV2xfZgxW0GQR1XS
UACC-62MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF5Lke2N|ch|ryPMmPaV2FPT0WU
BHT-101NXL4W5pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTF7Lki3NFUh|ryPM{nFc3NCVkeHUh?=
DBMk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvsS3hKSzVyPUKxMlU3PDlizszNNHTDNpNUSU6JRWK=
SK-MEL-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjyU2FKSzVyPUKxMlU5PzJizszNNFjBOndUSU6JRWK=
NCI-H747MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1za[2lEPTB;MkKuO|M4QSEQvF2=NV\4SWY5W0GQR1XS
SK-LU-1MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTJ|LkO1NlQh|ryPM{ftZnNCVkeHUh?=
KG-1M1i2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTJ|LkS5OFYh|ryPNY\vXYdVW0GQR1XS
LXF-289NFzWeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfyemNZUUN3ME2yN{44OTRizszNNYqxW25lW0GQR1XS
HCC1954NH\Dc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTJ2Lki4OFQh|ryPMn7LV2FPT0WU
Ramos-2G6-4C10M2jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfGXGRKSzVyPUK2MlQ6QDFizszNNEfjWpJUSU6JRWK=
DBTRG-05MGM2m3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTJ4Lk[0PFgh|ryPMofYV2FPT0WU
NCI-H2052MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXySXhKSzVyPUK3MlU3QDRizszNMl3LV2FPT0WU
RMG-IM3HofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2r4fGlEPTB;MkmuOFE{QSEQvF2=MXLTRW5ITVJ?
H9NYLwfGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHMSZl{UUN3ME2zNU4{ODB6IN88US=>NVTtRot{W0GQR1XS
GR-STM{jNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXsTWM2OD1|Mj60OFU{KM7:TR?=NVXXRYh6W0GQR1XS
Mo-TMnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIm2V4tKSzVyPUOyMlUxPDZizszNNUHpNYZYW0GQR1XS
SW1088NU\SSJpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULJcoVuUUN3ME2zNk46QDBzIN88US=>MlHiV2FPT0WU
LB2518-MELMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jYZmlEPTB;M{OuNFc6PyEQvF2=MWnTRW5ITVJ?
NCI-H82NWnueZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTN|LkG2OlEh|ryPM1PQPXNCVkeHUh?=
LAMA-84Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFH6bWlKSzVyPUO0MlYxPzNizszNNEfrTVdUSU6JRWK=
KYSE-450MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTN2Lk[3O|Yh|ryPMlXEV2FPT0WU
LU-99ANWXjVHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzUblAzUUN3ME2zOU4xODB5IN88US=>Ml3KV2FPT0WU
BE-13NULtRXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTN3Lk[1OFUh|ryPMUjTRW5ITVJ?
GAKNX3UdVRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LoUWlEPTB;M{WuOlk2KM7:TR?=MUfTRW5ITVJ?
NCI-H1573NFL5NXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULGXo9CUUN3ME2zOU45QDF6IN88US=>NYC5VVl1W0GQR1XS
AsPC-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TPe2lEPTB;M{[uNVUzPyEQvF2=NUXlb|NbW0GQR1XS
HDLM-2MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzxbZZKSzVyPUO2MlMyPiEQvF2=MXTTRW5ITVJ?
NCI-H441NWT0[GxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTN5LkC2PVEh|ryPM{LpbnNCVkeHUh?=
CAL-27M{m2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3NUYJ1UUN3ME2zO{44OjNzIN88US=>NHPVU|JUSU6JRWK=
OVCAR-3NWL4eWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnaW5pkUUN3ME2zPU4{OThzIN88US=>M13BfXNCVkeHUh?=
RPMI-8226Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TLdGlEPTB;M{muOVk5KM7:TR?=MUPTRW5ITVJ?
EFO-21MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmzTWM2OD12MD61PFE1KM7:TR?=NInYcHVUSU6JRWK=
SNU-C2BMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTRzLkWwPFQh|ryPMorUV2FPT0WU
VM-CUB-1NHrEUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvITWM2OD12Mz64NFM4KM7:TR?=M4OwUXNCVkeHUh?=
NCI-H2087MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHj[nFsUUN3ME20OU4xOjN|IN88US=>NH;3N2lUSU6JRWK=
EW-16NGPzSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4POPGlEPTB;NE[uN|E{PyEQvF2=M1ruUnNCVkeHUh?=
SK-N-ASNIjG[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTR4LkexOlch|ryPM4DYSHNCVkeHUh?=
COR-L105MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTR4Lki4OVch|ryPMnHiV2FPT0WU
DELMlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzGeFdlUUN3ME20PE4xPDJ7IN88US=>MWDTRW5ITVJ?
JVM-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTR6LkC1OVgh|ryPNVjEZlFiW0GQR1XS
KARPAS-45MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXXNXgyUUN3ME20PU41PTN6IN88US=>NVTzTZJ5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Protocol(Only for Reference)

Kinase Assay: [3]

Biacore studies Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel

Cell Assay: [2]

Cell lines OSA, T778, RMS13, U2OS, SaOS-2
Concentrations ~5 μM
Incubation Time 120 h
Method SRB

Animal Study: [1]

Animal Models SJSA-1 xenograft
Formulation 1% Klucel, 0.1% Tween 80
Dosages 50, 100, 200 mg/kg twice daily
Administration oral

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.

[2] Ohnstad HO, et al. BMC Cancer, 2011, 11(211), 1-11.

view more

Chemical Information

Molecular Weight (MW) 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms (-)-Nutlin-3
Solubility (25°C) * In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+1% hydroxyethyl cellulose+0.2% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-Piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Mdm2 Products

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Nutlin-3

    Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us